Profluent Announces $106M Funding Round

Why It Matters

The infusion of $106 million underscores strong investor confidence in AI-driven biotech and will enable Profluent to scale its platform, potentially shortening drug discovery timelines and reshaping how biological products are engineered across the industry.

Summary

Profluent, a frontier AI platform for protein design based in Emeryville, California, announced a $106 million financing round co-led by Altimeter Capital and Bezos Expeditions, with participation from existing backers Spark Capital, Insight Partners and Air Street Capital. The new capital brings the company’s total funding to $150 million and is earmarked to accelerate its mission of making biology programmable, targeting faster development of therapeutics, diagnostics, agriculture and biomanufacturing solutions. Profluent positions itself as a leader in applying advanced AI to protein engineering, aiming to transform multiple life‑science sectors.